Halia Therapeutics to Present Groundbreaking Data on Novel Allosteric NEK7 Inhibitor Ofirnoflast at the 2025 American Society of Hematology Annual Meeting

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

Halia-NEK7

More Like This

PR Newswire associated0

Halia Therapeutics Announces Positive Phase 2a Data for Ofirnoflast in Lower-Risk MDS at ASH 2025

PR Newswire associated0

Ofirnoflast (HT-6184) Receives Orphan Drug Designation from U.S. FDA for Myelodysplastic Syndromes

Halia Therapeutics Receives FDA Fast Track Designation for Ofirnoflast (HT-6184) in Lower-Risk Myelodysplastic Syndromes

PR Newswire associated0

Halia Therapeutics Completes Enrollment in Phase 2a Clinical Trial of HT-6184 for Myelodysplastic Syndrome (MDS)

PR Newswire associated0

Halia Therapeutics to Present Final Phase 2 Ofirnoflast Data in Lower-Risk MDS at EHA2026 and Announces Appointment of Han Myint, MD, FACP, as Chief Medical Officer

PR Newswire associated0

Halia Therapeutics Announces Presentation at the BIO Investment & Growth Summit

PR Newswire associated0

Halia Therapeutics to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference

PR Newswire associated0

Novo Nordisk to showcase new data across its hemophilia portfolio at the ISTH Congress 2026, featuring investigational denecimig